Ophthalmic Business News

Subject dosing is complete in a phase 1/2 clinical trial of an allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction, according to a press release.

In the rapidly evolving landscape of investments, it is crucial for physicians to stay informed about alternative asset classes, such as cryptocurrency.

Sight Sciences received a positive jury trial verdict of $34 million in a patent infringement case against Alcon and its Hydrus microstent, according to a press release.

BOSTON — In this Healio Video Perspective from the ASCRS meeting, William F. Wiley, MD, ABO, discusses his positive experience using Iheezo, a preservative-free ocular anesthetic for anterior segment surgery.

RevOpsis Therapeutics closed its first seed funding round and raised $16.5 million to advance RO-104, its lead candidate for the treatment of neovascular age-related macular degeneration.

Catch up on the most popular videos from Eyecelerator@ASCRS as Healio’s coverage of the American Society of Cataract and Refractive Surgery meeting continues.

BOSTON — In this Healio Video Perspective from the ASCRS meeting, John Sheets, PhD, of Pantheon Vision previews a product designed to address unmet needs in corneal blindness compared with the standard of care of transplantation.

In this episode, Cathleen McCabe, MD, and Susan MacDonald, MD, discuss their careers, their roles in humanitarian care and the importance of mentorship with Bonnie An Henderson, MD, and Abby Markward, MBA.

Ocular Therapeutix announced changes to its executive team, with Pravin U. Dugel, MD, assuming the roles of president and CEO and Antony Mattessich stepping down from these positions, effective immediately.

BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, Richard Small, CEO of Neurotech Pharmaceuticals, gives an update on encapsulated cell therapy for the extended treatment of retinal diseases.